| Overview |
| bs-9183R |
| VGLL2 Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VGLL2 |
| 101-200/317 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 245806 |
| Protein VITO1; Transcription cofactor vestigial like 2; Transcription cofactor vestigial like protein 2; Transcription cofactor vestigial-like protein 2; Vestigial like 2; Vestigial like 2 Drosophila; Vgl-2; VGL2; VGLL 2; Vgll2; VGLL2_HUMAN; VITO1. |
| Vgl-2, also known as VITO-1, is a 317 amino acid protein that contains a domain through which it interacts with TEF-1, a protein that plays a role in controlling the expression of numerous genes. Specific to skeletal muscle, Vgl-2 is expressed highly in adult fast muscle and is expressed at lower levels in adult slow muscle and fetal skeletal muscle. During muscle differentiation, Vgl-2 mRNA levels increase and Vgl-2 translocates from the cytoplasm to the nucleus. Overexpression of Vgl-2 in MYOD-transfected 10T1/2 mouse embryonic fibroblasts increases expression of myosin heavy chain (MHC), which is a marker of terminal muscle differentiation. This evidence suggests that Vgl-2 is essential for muscle gene expression. There are two isoforms of Vgl-2 that are produced as a result of alternative splicing events. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz